Ribociclib is one of the cyclin-dependent kinase 4 and 6 inhibitors (whose molecular formula is C23H30N8O3) approved by the FDA for the treatment of metastatic or advanced breast cancer with positive hormone receptors and HER-2 negative. The gene discussed is CDK4; the disease is breast carcinoma.